戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 omly reassigned to either 50 mg or 100 mg of sirukumab.
2                                              Sirukumab, a human monoclonal antibody that selectively
3 ized COVID-19 patients who were treated with sirukumab, an IL-6 neutralizing antibody, in a randomize
4  evaluated for the pharmacodynamic effect of sirukumab and for their potential prognostic and predict
5  including early escape patients switched to sirukumab at week 18] of 294; 194 [66%] of 292 with 50 m
6 tly randomly reassigned at week 24 to either sirukumab dose (crossover).
7 very 4 weeks and 0.21 (0.14-0.29) for 100 mg sirukumab every 2 weeks (both p<0.0001).
8 ry 4 weeks, and 132 (45%) of 292 with 100 mg sirukumab every 2 weeks versus 71 (24%) of 294 with plac
9 umab every 4 weeks, and 41 [14%] with 100 mg sirukumab every 2 weeks).
10 ry 4 weeks; and 207 [71%] of 292 with 100 mg sirukumab every 2 weeks).
11 very 4 weeks and 66 [16%] of 418 with 100 mg sirukumab every 2 weeks).
12 ks, 50 mg sirukumab every 4 weeks, or 100 mg sirukumab every 2 weeks, all given for 52 weeks or less.
13 g sirukumab every 4 weeks, and 292 to 100 mg sirukumab every 2 weeks.
14 acebo were 0.16 (95% CI 0.09-0.23) for 50 mg sirukumab every 4 weeks and 0.21 (0.14-0.29) for 100 mg
15 ion-site erythema (33 [8%] of 416 with 50 mg sirukumab every 4 weeks and 66 [16%] of 418 with 100 mg
16  at week 16 were 117 (40%) of 292 with 50 mg sirukumab every 4 weeks, and 132 (45%) of 292 with 100 m
17 s to treatment: 294 to placebo, 292 to 50 mg sirukumab every 4 weeks, and 292 to 100 mg sirukumab eve
18  (four [1%] with placebo, 22 [8%] with 50 mg sirukumab every 4 weeks, and 41 [14%] with 100 mg siruku
19 ystem to either placebo every 2 weeks, 50 mg sirukumab every 4 weeks, or 100 mg sirukumab every 2 wee
20 week 18] of 294; 194 [66%] of 292 with 50 mg sirukumab every 4 weeks; and 207 [71%] of 292 with 100 m
21 e aimed to assess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (S
22 aneous injection; patients assigned to 50 mg sirukumab given every 4 weeks also received a placebo in
23        At week 52, of all patients receiving sirukumab including those reassigned from placebo, the m
24 ts with critical COVID-19 without detectable sirukumab-induced IL-4 levels are more likely to benefit
25 nd March 2021, 209 patients were randomized (sirukumab, n = 139; placebo, n = 70); 112 had critical C
26  IL-4 levels are more likely to benefit from sirukumab treatment.
27 ificantly associated with better response to sirukumab (versus placebo) treatment for all clinical ef
28 ological treatments, both dosing regimens of sirukumab were well tolerated and significantly improved